CEO of Raygent Associates
Contributor's Links: Raygent

Rod Raynovich is an entrepreneur and executive with a focus on life science companies and medical technology trends.He has over 35 years executive experience including Abbott and JNJ and has been involved three successful start-ups. Before starting Raygent and other companies he was also a ... more

ALL CONTRIBUTIONS

Biotech Movers During ASCO Week
The biotech sector performed well in a good ASCO week. And many biotech stocks were movers this week as a bullish sentiment took hold sparked by the Biogen Aduhelm approval.
Read
Biotech Stocks Cruise Through The Volatility
The XLV Healthcare Select SPDR is up 10% YTD.
Read
Biopharma Stocks Stall After Earnings, Lag Over 52 Weeks
It is hard to forecast with the current choppy setting in the biopharma sector, but assuming that the COVID-19 vaccinations are on track in the U.S., financial results should improve for most large-cap biopharmas.
Read
How To Play Lagging Healthcare Stocks
The Healthcare Select SPDR Fund (XLV​​​​​​​) gives you the most diversified play in healthcare returning 11.4% in ’20 and 4% YTD.
Read
Healthcare Stocks To Own While We Wait For The Momentum Trades
Small-cap momentum trades are fading-the XBI is a key bellwether.
Read
Healthcare Stocks Are Fading: Over-Owned Or Rotation Effect?
Large Biopharma stocks still offer growth and value.
Read

Comments

Latest Comments
Regulatory News For Rare Disease Products - Hot Stocks: BLUE, ICPT, SRPT
6 years ago

Getting trial information and following them is the hard part as it takes too much time. Just sett up the stocks in a Yahoo portfolio and track daily. The WEB site of the Company usually lets you know if trial results are coming in and when.

In this article: BLUE, ICPT, SRPT
Biotech Buzz Is Broken
6 years ago

Here is the YTD for KITE down 4.7%:

www.google.com/finance

In this article: JUNO, KITE, GILD, REGN
2015 Biotech Stock Preview: Rhythms Of The “PermaBull”
6 years ago

prefer a fund like FBIOX but XBI will work when the market heats up

In this article: XLV, FBT, FBIOX, GILD
1 to 3 of 3 comments

STOCKS I FOLLOW

TWEETS

PERSONAL BLOG

Latest Posts
Biotech Investing Strategy For 2020: Part I… Update-1 Jan 24
We remain on hold for taking on new positions. Biotech and healthcare stocks have made nice gains so let’s get through the earnings cycle.
Asco Rally Fizzles: The Nascent Rally In Biotech Stocks Fades
ASCO Rally Fizzles Two Weeks ahead of May 31-June 4 Meeting: XBI down 0.9% to $83.

Work Experience

CEO
Raygent Associates
January 1990 - Present (31 years 11 months)
Biotechnology Intelligence www.raygent.com

Education

Penn State University
BS
Biochemistry
Rutgers University
MBA
Business

Publications